Two drug developers that operate in Wilmington, Del., are collaborating on a study that will test a combination of their products as a second-line treatment for lung cancer.
Under the partnership, Incyte Corp. will conduct a phase-I/II study of a treatment regimen that combines its experimental INCB39110 therapy, categorized as a kinase inhibitor, with Tagrisso, an AstraZeneca’s lung cancer drug approved in November.
Tagrisso, also a kinase inhibitor, is the only FDA-approved medicine for adult patients with what is known as “metastatic EGFR T790M mutation-positive non-small cell lung cancer.”
Read the full story here.
For more business news, visit PBJ.com.
Copyright bizjournal
